Caribou Biosciences, Inc.
CRBU- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001619856
No open-market purchases or sales by Caribou Biosciences, Inc. insiders were filed in the last 90 days; 137 institutions reported holding it in 13F filings for Q2 2026, worth $84.8M in total; Maverick Capital is the only superinvestor holding it.
13F holders, Q4 2025
Institutional positions in Caribou Biosciences, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 124
- +11 vs. Q3 2025
- Shares held
- 37.1M
- +110.9K (+0.3%) vs. Q3 2025
- Total value
- $58.8M
- −$27.8M (−32.1%) vs. Q3 2025
- New holders
- 25
- 28 more added
- Sold out
- 14
- 36 more reduced
4 institutions that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CRBU on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 137 | $84.8M |
| Q1 2026 | 137 | $71.3M |
| Q4 2025 | 124 | $58.8M |
| Q3 2025 | 117 | $87.0M |
| Q2 2025 | 129 | $51.2M |
| Q1 2025 | 131 | $45.8M |
| Q4 2024 | 133 | $93.1M |
| Q3 2024 | 129 | $103.1M |
| Q2 2024 | 140 | $87.6M |
| Q1 2024 | 151 | $343.0M |
| Q4 2023 | 144 | $395.8M |
| Q3 2023 | 126 | $338.5M |
| Q2 2023 | 121 | $185.5M |
| Q1 2023 | 126 | $238.3M |
| Q4 2022 | 133 | $273.8M |
| Q3 2022 | 113 | $456.8M |
| Q2 2022 | 120 | $203.0M |
| Q1 2022 | 104 | $313.2M |
| Q4 2021 | 93 | $464.7M |
| Q3 2021 | 88 | $704.7M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Caribou Biosciences, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Goldman Sachs Group Inc | 489,138 | $777.7K | 0.00% | +244,314+99.8% | Added |
| Citadel Advisors LLC | 515,429 | $819.5K | 0.00% | +250,306+94.4% | Added |
| Charles Schwab Investment Management Inc | 555,628 | $883.4K | 0.00% | −2,846−0.5% | Reduced |
| Cambridge Investment Research Advisors, Inc. | 581,793 | $925.0K | 0.00% | −594−0.1% | Reduced |
| UBS Group AG | 637,745 | $1.01M | 0.00% | +318,453+99.7% | Added |
| Maverick Capital LtdSuperinvestorMaverick Capital | 652,542 | $1.04M | 0.01% | 00.0% | Unchanged |
| FMR LLC | 725,968 | $1.15M | 0.00% | −3,034−0.4% | Reduced |
| Millennium Management LLC | 767,002 | $1.22M | 0.00% | −2,449,533−76.2% | Reduced |
| Jacobs Levy Equity Management, Inc | 824,299 | $1.31M | 0.01% | +475,216+136.1% | Added |
| Marshall Wace, LLP | 881,105 | $1.40M | 0.00% | +755,261+600.2% | Added |
| PFM Health Sciences, LP | 957,787 | $1.52M | 0.15% | −401,044−29.5% | Reduced |
| Geode Capital Management, LLC | 976,813 | $1.55M | 0.00% | −8,313−0.8% | Reduced |
| Bank of America Corp | 993,186 | $1.58M | 0.00% | −81,256−7.6% | Reduced |
| Dimensional Fund Advisors LP | 1,006,010 | $1.60M | 0.00% | −204,300−16.9% | Reduced |
| Two Sigma Investments, LP | 1,020,079 | $1.62M | 0.00% | +236,489+30.2% | Added |
| Susquehanna International Group, LLP | 1,031,375 | $1.64M | 0.00% | +585,768+131.5% | Added |
| Two Sigma Advisers, LP | 1,115,700 | $1.77M | 0.00% | −111,700−9.1% | Reduced |
| Standard Life Aberdeen plc | 1,388,905 | $2.21M | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 1,639,857 | $2.61M | 0.00% | +859,436+110.1% | Added |
| BlackRock, Inc. | 2,141,023 | $3.40M | 0.00% | +681,703+46.7% | Added |
| Kynam Capital Management, LP | 2,503,302 | $3.98M | 0.26% | −564,472−18.4% | Reduced |
| Vanguard Group Inc | 4,304,198 | $6.84M | 0.00% | +77,272+1.8% | Added |
| Pfizer Inc | 4,690,431 | $7.46M | 3.15% | 00.0% | Unchanged |
| DekaBank Deutsche Girozentrale | 130,000 | – | – | 00.0% | Unchanged |
| Pale Fire Capital SE | 0 | $0 | 0.00% | −775,055−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −558,576−100.0% | Sold out |
| Catalyst Funds Management Pty Ltd | 0 | $0 | 0.00% | −88,300−100.0% | Sold out |
| Thrivent Financial for Lutherans | 0 | $0 | 0.00% | −35,562−100.0% | Sold out |
| Susquehanna Portfolio Strategies, LLC | 0 | $0 | 0.00% | −29,883−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −21,123−100.0% | Sold out |
| R Squared Ltd | 0 | $0 | 0.00% | −12,268−100.0% | Sold out |
| Wealthspire Advisors, LLC | 0 | $0 | 0.00% | −7,500−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −6,084−100.0% | Sold out |
| Advisory Services Network, LLC | 0 | $0 | 0.00% | −914−100.0% | Sold out |
| Rise Advisors, LLC | 0 | $0 | 0.00% | −548−100.0% | Sold out |
| Principal Securities, Inc. | 0 | $0 | 0.00% | −270−100.0% | Sold out |
| Essential Partners LLC | 0 | $0 | 0.00% | −157−100.0% | Sold out |
| EverSource Wealth Advisors, LLC | 0 | $0 | 0.00% | −24−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | – | – | – | – | Not filed |
| Point72 Asia (Singapore) Pte. Ltd. | – | – | – | – | Not filed |
| FSA Wealth Management LLC | – | – | – | – | Not filed |
| Point72 (DIFC) Ltd | – | – | – | – | Not filed |